Prior receipt of investigational anti-HIV vaccine
Ongoing therapy with any of the following: Systemic corticosteroids. Short course less than or equal to 21 days of corticosteroids is allowed; Systemic chemotherapeutic agents; Nephrotoxic systemic agents, including aminoglycosides, amphotericin B, cidofovir, cisplatin, foscarnet, pentamidine; Immunomodulatory treatments including Interleukin-2; Investigational agents
Known allergy/sensitivity or any hypersensitivity to components of study drugs (ART) or their formulations
Active drug or alcohol use or dependence that would interfere with adherence to study requirements
Serious medical or psychiatric illness that would interfere with the ability to adhere to study requirements
Chronic or acute hepatitis B infection
Use of female hormonal products based on estrogen or derivatives

NCT01815580_exc_T1
Temporal
Prior
NCT01815580_exc_T2
Qualifier
investigational
NCT01815580_exc_T3
Drug
anti-HIV vaccine
NCT01815580_exc_T4
Temporal
Ongoing
NCT01815580_exc_T5
Procedure
therapy
NCT01815580_exc_T6
Drug
Systemic corticosteroids
NCT01815580_exc_T7
Multiplier
Short course
NCT01815580_exc_T8
Multiplier
less than or equal to 21 days
NCT01815580_exc_T9
Condition
corticosteroids
NCT01815580_exc_T10
Negation
is allowed
NCT01815580_exc_T11
Scope
Short course less than or equal to 21 days of corticosteroids is allowed
NCT01815580_exc_T12
Drug
Systemic chemotherapeutic agents
NCT01815580_exc_T13
Drug
Nephrotoxic systemic agents
NCT01815580_exc_T14
Drug
aminoglycosides
NCT01815580_exc_T15
Drug
amphotericin B
NCT01815580_exc_T16
Drug
cidofovir
NCT01815580_exc_T17
Drug
cisplatin
NCT01815580_exc_T18
Drug
foscarnet
NCT01815580_exc_T19
Drug
pentamidine
NCT01815580_exc_T20
Procedure
Immunomodulatory treatments
NCT01815580_exc_T21
Drug
Interleukin-2
NCT01815580_exc_T22
Drug
Investigational agents
NCT01815580_exc_T23
Scope
Systemic corticosteroids. Short course less than or equal to 21 days of corticosteroids is allowed; Systemic chemotherapeutic agents; Nephrotoxic systemic agents, including aminoglycosides, amphotericin B, cidofovir, cisplatin, foscarnet, pentamidine; Immunomodulatory treatments including Interleukin-2; Investigational agents
NCT01815580_exc_T24
Condition
allergy
NCT01815580_exc_T25
Condition
sensitivity
NCT01815580_exc_T26
Condition
hypersensitivity
NCT01815580_exc_T27
Drug
components of study drugs
NCT01815580_exc_T28
Drug
ART
NCT01815580_exc_T29
Drug
or their formulations
NCT01815580_exc_T30
Scope
components of study drugs (ART) or their formulations
NCT01815580_exc_T31
Condition
alcohol use
NCT01815580_exc_T32
Condition
use
NCT01815580_exc_T33
Condition
g or endence th
NCT01815580_exc_T34
Condition
ohol us endence th
NCT01815580_exc_T35
Qualifier
would interfere with adherence to study requirements
NCT01815580_exc_T36
Scope
drug or alcohol use or dependence
NCT01815580_exc_T37
Temporal
Active
NCT01815580_exc_T38
Condition
psychiatric illness
NCT01815580_exc_T39
Condition
cal or ess tha
NCT01815580_exc_T40
Qualifier
Serious
NCT01815580_exc_T41
Scope
medical or psychiatric illness
NCT01815580_exc_T42
Qualifier
would interfere with the ability to adhere to study requirements
NCT01815580_exc_T43
Condition
ic or a itis B infection
Use
NCT01815580_exc_T44
Condition
acute hepatitis B infection
NCT01815580_exc_T45
Drug
female hormonal products
NCT01815580_exc_T46
Qualifier
en or de tives
NCT01815580_exc_T47
Qualifier
estrogen
NCT01815580_exc_T48
Scope
estrogen or derivatives